Clinical trials: Persistent Cervical Cancer
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00039442
- Testing
- Capecitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gynecologic Oncology Group
Head and Neck Cancer, Lung Cancer
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
- Trial name
- ALTAK (NCT01647425)
- Testing
- physician assessment
- Where
- 3 sites in France
- Volunteers
- 385 people
- Sponsor
- Centre Oscar Lambret
Cervical Cancer
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness liposomal doxorubicin in treating patients who have…
- Trial name
- NCT00030472
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 17 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00803062
- Testing
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis
- Where
- 549 sites in United States, Spain
- Volunteers
- 452 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Ovarian Cancer, Ovarian Carcinoma
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical…
- Conditions
- Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer
- Trial name
- NCT06677190
- Testing
- Belzutifan
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Cervical Cancer, Cervical Cancer Recurrent
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent…
- Conditions
- Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
- Trial name
- NCT03614949
- Testing
- Stereotactic body radiation therapy (SBRT), Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nasopharyngeal Cancer, Epstein-Barr Virus Infections
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
The purpose of this study is to evaluate the efficacy (clinical benefit rate) of MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal carcinoma, and its impact on disease progression.
- Trial name
- NCT01094405
- Testing
- Recombinant Epstein-Barr Virus (EBV) Vaccine
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Chinese University of Hong Kong
Cervical Cancer, Cervix Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Cervical Cancer, Cervix Cancer, Cervix Neoplasm
- Trial name
- NCT04651127
- Testing
- Toripalimab + Chidamide
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
This phase II trial is to see if bevacizumab works in treating patients who have persistent or recurrent cancer of the cervix. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Trial name
- NCT00025233
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer
- Trial name
- NCT00548418
- Testing
- Topotecan, Cisplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
This is a updated trial of NCT04188860 as a multi-center study. For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Immune Checkpoint Inhibitors
- Trial name
- NCT05290935
- Testing
- Anti-PD-1 antibody camrelizumab, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lei Li
Persistent, Recurrent, or Metastatic Cervical Cancer
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic…
- Trial name
- NCT05798819
- Testing
- GLS-010, paclitaxel, cisplatin
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Nasopharyngeal Carcinoma
Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma
Objectives: Primary objective To determine the efficacy of Foscan-PDT compared with Brachytherapy for recurrent or persistent NPC, as determined by macroscopic clinical examination, CT scan and biopsy.
- Trial name
- FOSCAN (NCT01086488)
- Testing
- FOSCAN
- Where
- 5 sites in Malaysia
- Volunteers
- 66 people
- Sponsor
- Ministry of Health, Malaysia
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7
- Trial name
- NCT02257528
- Testing
- Laboratory Biomarker Analysis, Nivolumab
- Where
- 331 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
This study was an open, single-arm, enriched, multicenter Phase II study.
- Trial name
- NCT06226350
- Testing
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Cervical Cancer
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT05179239
- Testing
- SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.